17 July 2020
MOH said last November that 4,500 Malaysians were treated with generics of sofosbuvir.
Tag: Gilead Sciences
26 May 2020
Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
22 May 2020
Wall Street analysts suggest remdesivir could be priced between US5,000-US10,000 for a 10-day course of treatment.
21 May 2020
Gilead Sciences has excluded Malaysia from receiving generic versions of remdesivir.
21 May 2020
Three Opposition MPs say Malaysia can’t afford to spend as much on health care as Singapore or other Asian countries like South Korea.
20 May 2020
The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements are Malaysia, Singapore, and Brunei.
19 May 2020
Letter
Include Malaysia And Other Middle-Income Countries in All Licensing Agreements For Covid-19 Diagnostics, Treatments, And Vaccines — MHC & DNDi
Gilead excluded Malaysia, among other middle-income countries, from distribution of Remdesivir to 127 nations under voluntary licensing.
12 May 2020
Unwarranted high prices for medications could lead to preventable deaths, said a study.
20 April 2020
The trial saw most patients with severe Covid-19 discharged within six days.